This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Treatment

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Seek specialist advice.

  • if non-ulcerated necrobiosis lipoidica (NL) then possible treatment measures include topical corticosteroids (e.g. application of steroid creams under occlusive dressings); also intralesional and systemic corticosteroids are possible treatment modalities (1). Topical PUVA appears to be a promising therapeutic option in the treatment of non-ulcerated NL
  • steroid use is beneficial to control the initial erythema in early lesions but fails to help with the atrophic component of the lesions and can worsen atrophy (2)
  • if ulcerated NL then there may be response to immunomodulating drugs such as cyclosporin and mycophenolate mofetil

Reference:

  1. British Journal of Diabetes and Vascular Disease 2005; 5(1):37-41.
  2. Duff M et al. Cutaneous Manifestations of Diabetes Mellitus.Clin Diabetes. 2015 Jan; 33(1): 40-48.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.